Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Neoplasms 1Glioblastoma 1Cognitive Dysfunction 1Chemotherapy-Related Cognitive Impairment 1Acute Kidney Injury 1

Interventions

Paclitaxel 9Carboplatin 8Bevacizumab 8fluzoparib 5olaparib 3Topotecan 3Gemcitabine 3liposomal doxorubicin 2famitinib 2apatinib 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Indocyanine Green 2Drug Therapy 2Cisplatin 2trametinib 1senaparib 1pembrolizumab 1niraparib 1montelukast 1irinotecan sucrosofate 1fludarabine 1durvalumab 1dalpiciclib 1dabrafenib 1ceralasertib 1anlotinib 1aldesleukin 1Ultrasonography, Doppler 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Ovarian Neoplasms × Acetylcysteine × Clear all
NCT04520139 2026-04-29

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

University of California, Irvine

Phase 1/2 Not yet recruiting
102 enrolled
Gynecologic

Chemotherapy-Related Cognitive Impairment, Ovarian Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡